NRX Pharma up on plans to start second psychiatry study

NRX Pharmaceuticals

15/08/2022 14:43

** NRX Pharmaceuticals Inc's shares  NRXP.O  up 5% at $0.84
    ** NRXP says it will begin a second study of its lead
experimental drug in patients with bipolar depression who have
acute suicidal tendencies by end of 2022 or beginning of 2023
 urn:newsml:reuters.com:*:nPn4s1P07a
    ** NRX-101 has already received U.S. FDA's Breakthrough
Therapy designation in the indication 
    ** The drug is already being tested in a mid-stage study in
patients with severe bi-polar depression who have sub-acute
suicidal tendencies  urn:newsml:reuters.com:*:nL3N2X440C
    ** Up to Friday's close, stock was down ~83% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com))